Global stock

NASDAQUSD

Ionis Pharmaceuticals

IONS

AI analysis and articles are in Czech.

§ Financial healthLong-term stability

35/ 100

Overall score·IONS

Current price

43.42USD

26/10/2026

P/E, P/B

Valuation

Weak

Rates whether the stock is cheap or expensive relative to its history and sector. A score above 60 suggests the stock trades below its estimated intrinsic value.

Tracks:P/E · P/B · FCF yield · sector

Záporný zisk, záporný forward P/E a vysoké násobky P/B a P/S ukazují na náročné ocenění vůči ztrátovému hospodaření. Růst tržeb meziročně klesl o 40,7 % a cena je pod 50denním i 200denním průměrem; relativně silnými stránkami jsou vysoká běžná likvidita a regulační milník Tryngolzy.

§ Outlook vs S&P 500Next 12 months

Probably not

Estimated chance of beating the index: about 45%

8 of 8 inputs

NoProbably notSameProbably yesYes

A model estimate from current values. The result may change with new data; it is not a price target or an investment recommendation.

§ Context and events

Management

Brett P. Monia je zakladatel, CEO a člen představenstva. Elizabeth L. Hougen zastává funkci finanční ředitelky, Patrick R. O'Neil vede právní agendu a Eric E. Swayze řídí výzkum. Strategie společnosti stojí na vývoji antisense léčiv a jejich uvádění na trh, samostatně i prostřednictvím partnerství.

Articles about Ionis Pharmaceuticals, in Czech (0)

No articles yet. New analyses are published daily.

§ Upcoming results

4 November 2026

in 8 days

Earnings

Earnings = quarterly financial results (revenue and profit). Companies publish them every three months and the share price often reacts strongly.

§ Frequently asked questions

What is Ionis Pharmaceuticals (IONS)?

Ionis Pharmaceuticals (IONS) is a global stock traded on NASDAQ. Sector: Healthcare. We track it daily — scoring news sentiment, the short-term outlook and long-term stability on a 0–100 scale.

What is the Ionis Pharmaceuticals price today?

As of 26 October 2026, Ionis Pharmaceuticals trades at about 43.42 USD per unit. We update the price daily from public market data. Intraday moves can differ significantly — always check the final price with your broker.

How to buy Ionis Pharmaceuticals?

Through regulated online brokers such as Degiro, XTB, Trading 212 or Interactive Brokers. Shares trade in USD or EUR — most brokers convert your currency automatically. FinSignal does not operate any of these platforms and charges no commission — the overview is only a signpost.

Does Ionis Pharmaceuticals pay a dividend?

Ionis Pharmaceuticals either pays no dividend at the moment or we have no reliable data on it. Many growth companies prefer reinvesting profit to paying dividends — check the current policy in the company's investor relations materials.

Is Ionis Pharmaceuticals a good investment in 2026?

Our AI signal currently rates Ionis Pharmaceuticals as slightly positive (score 65/100). Financial health comes out at 35/100, so beyond short-term news it is worth watching the valuation, growth, profitability and stability of the company. FinSignal is not an investment adviser licensed under Czech Act No. 256/2004 Coll. — signals are analytical input, not a recommendation to buy or sell. You make every decision at your own risk.

§ More global stocks

Microsoft Corporation

MSFThealth 73/100

§ How to buy Ionis Pharmaceuticals

You can buy shares through regulated online brokers available in the EU. They differ mainly in fees, app quality and which markets they cover.

Degiro
Dutch broker with low fees for passive investors. No account fee, trading in EUR and USD.
XTB
Polish broker with zero commission on stocks and ETFs up to EUR 100,000 a month. Own xStation platform.
Trading 212
Zero-commission broker with fractional shares from EUR 1 and automated investing (Pies). Suits beginners and regular investing.
Interactive Brokers
US broker for advanced investors. The widest choice of markets, low costs at larger volumes, a professional platform with a steeper learning curve.

FinSignal operates none of these platforms. We charge no commission on purchases.

Important: Signals are an analytical tool, not investment advice within the meaning of Czech Act No. 256/2004 Coll. Past performance does not guarantee future results. You make all decisions at your own risk.

§ Current signalShort-term mood

/ 100

● Slightly positive

Earnings in 8 days

On 4 November 2026 the company publishes its quarterly results. This period tends to bring large price moves.

News summary

Older news

Signal 23/10, 22:02

Ionis hlásí nové pozitivní výsledky fáze 3 u sefaxersenu; FDA také udělila označení pro vzácnou epilepsii. Dopad posílí, pokud se promítne do dalších schválení či partnerských příjmů.

Pozitivní zprávy a růst ceny za týden podporují výhled, ale měsíční pokles, RSI 40 a slabé momentum jej tlumí. Vývoj společnosti těží z partnerského portfolia, jehož komerční přínos se může lišit.

Risks: Pohled by oslabil neúspěch navazujících studií či schvalování nebo další pokles ceny při přetrvávajícím slabém momentu.

More about the signal

Risks: Pohled by oslabil neúspěch navazujících studií či schvalování nebo další pokles ceny při přetrvávajícím slabém momentu.

Signal history· 2

21/1019:0270 · Slightly positive
GSK a Ionis získaly americké schválení Hibsaga, který ve studiích s antivirotiky vedl k funkční remisi asi u pětiny pacientů; dopad na Ionis závisí na ekonomice partnerství a uvedení léku.
21/1004:0264 · Slightly positive
GSK oznámila schválení Hibsaga v USA; Ionis je partnerem. Úspěch může podpořit partnerský program, dopad na Ionis však závisí na jeho ekonomickém podílu.

The full 90-day signal history is part of Premium.

Ask the AI

DCF valuation

A DCF model is not suitable for this asset class.

§ Valuation check

Is the price reasonable?

Six quick tests: price against fair value, the last year, similar companies and analyst estimates. They are calculated from the numbers, not from AI estimates. This is not a recommendation.

Data 16 of 18

Valuation score

2/ 6

3/6 tests available

1. Below DCF fair value

The complete DCF range or the current price is missing.

2. Well below DCF value

The complete DCF range or the current price is missing.

3. Price vs. the last year

2% above the 1-year low (42.38 USD to 86.50 USD), based on stored daily prices.

4. P/E vs. similar companies

The sector sample has only 72 companies; scoring needs at least 8.

5. P/E relative to growth

PEG 27.3; a lower value means cheaper growth.

6. Analyst price target

93.8% vs. the current price, 23 analysts.

Price and fair value

no complete range

The DCF check appears once both the price and the model range are available.

Price vs analyst target

Current price

43.42 USD

Low 58.00 USDHigh 105.0 USD

Current priceAverage: 84.13 USD

DCF gap

no complete range

The DCF check appears once both the price and the model range are available.

Analyst target

+93.8%

Average target 84.13 USD vs. price 43.42 USD.

Analyst consensus

Target range

58.00 USD - 105.0 USD

Coverage

23 analysts

Analyst consensus

1.7 / 5

Changes 180 d

+2 / -1

EPS next year

56.3%

Revenue next year

47.4%

Valuation multiples

-37.9

16.4

8.3

-12.6

27.3

52-week range2% above the low

42.38 USD86.50 USD

-41.0%

-64.7%

-105.5%

Price vs 50D-13.6%

Price vs 200D-35.7%

Metrics explained+

Price and fair value

DCF range: A model estimate of fair value from future free cash flow. A price above the range means the market pays a premium over the model; a price below it may signal a more conservative market valuation or an overly optimistic model.
Analyst target: The average and range of the analyst price targets we track. It is the market consensus, not a FinSignal recommendation, and it can lag fast price moves.
52-week range: Shows where the current price sits between the low and high of the last year. A value near the high often signals strong momentum, but on its own says nothing about whether the stock is expensive.
Price vs 50D / 200D: Compares the price with its short- and long-term moving averages. A positive value means the price is above the trend; a negative one below it.

Multiples

P/E: Price relative to current earnings. A lower P/E can mean cheaper, but it can also point to a weak outlook or risk.
Forward P/E: Price relative to next year's expected earnings. For growing companies it is often more useful than the historical P/E because it reflects estimates of future earnings.
P/B: Price relative to the book value of equity. It makes more sense for banks, insurers and capital-intensive companies than for software or brands.
P/S: Price relative to revenue. It helps with companies that have low or negative earnings; a high P/S means the market expects strong growth or future margins.
EV/EBITDA: The value of the whole company, including debt, relative to operating profit before depreciation. Useful for comparing companies with different leverage.
PEG: P/E adjusted for earnings growth. A value around 1 may suggest the valuation matches growth, but the metric is sensitive to estimates.

Growth and quality

EPS growth: Year-on-year change in earnings per share. Strong growth supports a higher valuation, but for cyclical companies it can be temporary.
Revenue growth: The growth rate of sales. It helps tell whether profits grow on real demand or mainly on cost savings.
Net margin: How much of each unit of revenue is left as net profit. A higher margin often points to stronger pricing power or more efficient operations.
ROE: Return on equity. A high ROE can signal a quality business, but check that it is not artificially boosted by heavy debt.

Most data available. Missing values mean the market data source did not provide them for this ticker. The data is indicative and may be delayed. Price as of 26/10/2026.

Management and competitive advantage

Both are estimated by the AI from the company profile, news and results. They do not count towards the 6-pillar financial health score. The AI comments are in Czech.

strong

Zakladatel v čele společnosti a zkušený tým podporují kontinuitu strategie, zatímco vývojová rizika a závislost na partnerských programech zůstávají významné.

strong

Vlastní technologie antisense léčiv, klinické know-how a partnerství s velkými farmaceutickými společnostmi tvoří konkurenční výhodu, jejíž trvanlivost závisí na klinickém úspěchu a komerčním uplatnění.

Information

Type: Global stock
Symbol: IONS
Exchange: NASDAQ
Currency: USD
Sector: Healthcare
: 7.2B USD
: 497.8 %
: 0.38

§ Risk profile

Výnos akcie může prudce reagovat na klinické výsledky, rozhodnutí FDA a komerční úspěch nových léků. Český investor navíc nese měnové riziko USD/CZK.

Ask the AI about Ionis Pharmaceuticals All signals